UpdatesPress Release (Revised)
Alembic Pharma reported strong Q1 FY27 results: Revenue up 26% to Rs 2150 Cr, PAT up 12% to Rs 173 Cr.
Alembic Pharmaceuticals LimitedAPLLTD · Filed with the exchange
Growth was broad-based, with US Formulation up 49% and API up 33%. New launches and ANDA approvals drove performance.
An investor call is scheduled.
No comments yet. Be the first.